Romosozumab does not improve volumetric bone mineral density at distal radius but is associated with early changes in bone strength: a prospective study
Authors' conclusion
ROMO treatment was associated with modest early changes in biomechanical parameters, without significant improvement in vBMD at the distal radius.
Study context
- Population
- Postmenopausal women with osteoporosis treated with romosozumab
- Participants
- 49 women
- Outcome
- Distal radius vBMD, microarchitecture and biomechanical properties (high-resolution peripheral quantitative computed tomography (HR-pQCT), uFEA)
- Follow-up
- 12 months
Methodological detailssingle-group, mixed-effects modelling
- Single-group
- Mixed-effects modelling
Main finding
As reported in the abstract
Distal radius vBMD, microarchitecture and biomechanical properties (HR-pQCT)
- No significant increases in cortical or trabecular volumetric BMD (vBMD) or microarchitectural parameters at the distal radius
- Early increases in cortical failure load and shear strength (uFEA)
Observational data: associations, not effects.
Further findings
aBMD increase (DXA) · 12 months
- Lumbar spine
- 11.6%
- Femoral neck
- 8.3%
- Total hip
- 3.1%
- All p < 0.001
Original publication
Romosozumab does not improve volumetric bone mineral density at distal radius but is associated with early changes in bone strength: a prospective study. Osteoporos Int. Published 18 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →